/
Other
Ovarian
20
Pipeline Programs↗
22
Active Trials↗
20
Companies Involved↗
Ovarian is an emerging landscape with 20 programs across 20 companies. The most active players are AstraZeneca. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 13
Phase 22
Phase 36
Approved
No programs
Analysis
Modality Breakdown
90%
Small molecule
18 of 20 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.
Analysis
Trial Status
70
clinical trials
Completed32 · 46%
Unknown status14 · 20%
Recruiting8 · 11%
Not yet recruiting7 · 10%
Active, not recruiting6 · 9%
Enrolling by invitation1 · 1%
Other2 · 3%
Clinical Trials
Trial Activity
70 trials
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Recruiting·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT05440617·100 enrolled
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Recruiting·—·Phase 3·NCT02429700·132 enrolled
Effect of Rapamycin in Ovarian Aging
Active, not recruiting·—·Phase 2·NCT05836025·50 enrolled
New Strategy of Knowledge-Enhanced Large Model for Ultrasound Scanning and Diagnosis of Ovarian Masses
Not yet recruiting·WWomen's Hospital School Of Medicine Zhejiang University·N/A·NCT07801209·250 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)